Want to see HRGN full AI Analyst Report?
HRGN Stock Chart & Stats
$1.82
$0.07(2.66%)
At close: 4:00 PM EST
$1.82
$0.07(2.66%)
Day’s Range― - ―
52-Week Range$0.96 - $2.22
Previous CloseN/A
Volume1.21K
Average Volume (3M)1.13K
Market Cap
$18.81M
Enterprise Value$18.57M
Total Cash (Recent Filing)$419.00K
Total Debt (Recent Filing)$173.00K
Price to Earnings (P/E)―
Beta-0.26
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,580,744
10 Day Avg. Volume797
30 Day Avg. Volume1,125
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)28.75
Price to Sales (P/S)43.17
P/FCF Ratio-7.94
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue41.72
Enterprise Value/Gross Profit-49.64
Enterprise Value/Ebitda-2.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Milestone / Pipeline ProgressTreating the first patient in an FDA‑regulated Phase 1 trial is a durable program de‑risking event: it validates clinical feasibility, advances regulatory pathway work, and materially progresses the lead program toward later trials or partnerships, strengthening long‑term value drivers.
Strategic Clinical PartnershipsPartnerships with Mayo Clinic and IQVIA enhance trial execution, site access and data management. Such institutional collaborators improve enrollment, credibility with regulators and potential commercialization planning, providing durable operational advantages in clinical development.
Low Absolute Debt BurdenLow nominal debt reduces fixed financing obligations and bankruptcy risk in the near term. For a cash‑burning developer, limited debt gives some optionality versus high leverage, preserving flexibility while seeking equity or non‑dilutive funding over the coming months.
Bears Say
Sustained Negative Cash FlowPersistent negative operating and free cash flow consume balance‑sheet resources and force ongoing external financing. This structural cash burn creates execution risk for multi‑site clinical programs and raises the probability that development timelines will depend on successful future raises.
Minimal Revenue And Deep Operating LossesNegligible revenues against multi‑million operating losses indicate the business is not self‑sustaining. Large negative margins erode capital, limit reinvestment capacity, and mean near‑term progress hinges on capital markets or partners rather than internal cash generation.
Eroded Equity And Liquidity/Dilution RiskSeverely diminished equity reduces financial cushion and elevates debt‑to‑equity metrics despite low nominal debt. Combined with disclosed bridge financing and planned raises, this creates a durable risk of dilution or constrained operations if capital access tightens during clinical development.
Harvard Apparatus Regenerative Technology News
HRGN FAQ
What was Harvard Apparatus Regenerative Technology’s price range in the past 12 months?
Harvard Apparatus Regenerative Technology lowest stock price was $0.96 and its highest was $2.22 in the past 12 months.
What is Harvard Apparatus Regenerative Technology’s market cap?
Harvard Apparatus Regenerative Technology’s market cap is $18.81M.
When is Harvard Apparatus Regenerative Technology’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Harvard Apparatus Regenerative Technology’s earnings last quarter?
Currently, no data Available
Is Harvard Apparatus Regenerative Technology overvalued?
According to Wall Street analysts Harvard Apparatus Regenerative Technology’s price is currently Overvalued.
Does Harvard Apparatus Regenerative Technology pay dividends?
Harvard Apparatus Regenerative Technology does not currently pay dividends.
What is Harvard Apparatus Regenerative Technology’s EPS estimate?
Harvard Apparatus Regenerative Technology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Harvard Apparatus Regenerative Technology have?
Harvard Apparatus Regenerative Technology has 17,580,744 shares outstanding.
What happened to Harvard Apparatus Regenerative Technology’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Harvard Apparatus Regenerative Technology?
Currently, no hedge funds are holding shares in HRGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal system and various other organs, which may stem from cancer, trauma, or congenital defects. The company's primary experimental therapy, the Cellspan Esophageal Implant, aims to treat severe esophageal disease. Beyond this, its development pipeline encompasses organ-regeneration technologies designed for the repair or replacement of damaged or diseased organs. This includes product candidates targeting diverse esophageal ailments—such as those caused by traumatic injury, caustic burns, or tissue damage from chemoradiation therapy, as well as birth defects—and solutions for colon and uterine wound reconstruction. Additionally, the company offers consumer health products, including dietary supplements, focusing on personal wellness. Founded in 2009 and headquartered in Holliston, Massachusetts, the company operated as Biostage, Inc. until its rebranding to Harvard Apparatus Regenerative Technology Inc. in July 2023.
Technical Analysis
Lisata Therapeutics
―
Moleculin Biotech
―
Pulmatrix
―
SAB Biotherapeutics
―
Longeveron
―